September 30, 2022
2 min watch
Save
VIDEO: Opthea CEO discusses updates on OPT-302 for treatment of wet AMD
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this video from Eyecelerator@AAO, Opthea CEO Megan Baldwin, PhD, discusses updates for OPT-302, a therapy targeting a new mechanism of action for the treatment of wet age-related macular degeneration.
“We’re excited about it because it targets VEGF-C and VEGF-D, which are not currently targeted by the existing standard of care treatments,” she said.
Published by:
Sources/Disclosures
Collapse
Source:
Baldwin M. Opthea. Presented at: Eyecelerator@AAO; Sept. 29, 2022; Chicago.
Disclosures:
Baldwin reports being the CEO of Opthea.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.